Derepression of a mouse alpha-fetoprotein expression vector in COS-1 cells by amplification of specific cis-acting sequences of the AFP promoter.

The existence of trans-acting regulatory factors has been demonstrated by in vivo competition with cis-acting sequences from both viral and eukaryotic genomes. Plasmids containing a functional SV40 origin of replication when transfected into permissive SV40 T-antigen producing COS-1 cells will amplify to high copy numbers (5,000 to 10,000) without inflicting toxic effects upon the host cell. This amplification vector (pSVori) has been used to amplify cis-acting regulatory elements which can act as competitors for positive and negative trans-acting factors in vivo. Using this amplification system we conducted experiments to determine whether amplification of alpha-fetoprotein (AFP) and albumin cis-acting promoter sequences could activate a corresponding co-transfected AFP-promoter-CAT or Alb-promoter-CAT expression vector in COS-1 cells. We used pMoMLV(-1009)AFPcat, or p(-308)Albcat-MoMLV as reporter genes and pSVori to amplify specific promoter sequences of the AFP or albumin promoter. Our experiments indicated that amplification of a region from -53 to -202 of the AFP promoter resulted in the activation of the pMoMLV(-1009)AFPcat and p(-308)Albcat-MoMLV expression vectors in COS-1 cells. Surprisingly, amplification of the albumin promoter sequences failed to activate either the pMoMLV(-1009)AFPcat or p(-308)Albcat-MoMLV plasmids.     

Interaction of trans-acting factors with the proximal promoter of the mouse alpha-fetoprotein gene.

1. The alpha-Fetoprotein (AFP) gene is expressed during fetal life, but not in adult cells. Also, the AFP gene is expressed in most hepatomas. 2. Using gel retardation (band-shift) assays under very stringent conditions we have compared the binding of trans-acting factors to the proximal enhancer (-202, +34) region of the AFP gene. 3. We have detected the presence of two retarded bands in experiments performed with adult rat hepatocytes and the Fa32 cell line (which does not produce AFP) but only one band is observed with the HepG2 cell line (which produces AFP) and fetal liver. 4. We relate the two retarded bands to a glucocorticoid response element and, tentatively, to the C/EBP trans-acting fractor.     

Transient repression of the lac operon - the effect of a lac promoter deletion

Experiments have been done to show whether the lac promoter delection L1, which partly alleviates catabolite repression, also affects transient repression of lac. In stain L1/F'M15 all of the beta-galactosidase is synthesized from a chromosomal gene cis to L1, whereas 98% of the thiogalactosidase transacetylase is synthesized from an episomal gene cis to an intact i-p-o region. The addition of glucose to induced cultures of strain L1/F'M15 growing in glycerol medium caused extensive transient repression of transacetylase but almost no transient repression of beta-galactosidase. In control experiments with a diploid stain of genotype p(+)z(+)a(-)/F'p(+)z(-)a(+) the two enzymes suffered equal transient repression. Thus L1 substantially relieves transient repression.     

Re-initiation of tryptophan operon expression in a promoter deletion strain of Salmonella typhimurium.

Summary A genetic and enzymological study was made of five spontaneous prototrophic revertants of a tryptophan auxotroph of Salmonella typhimurium which carries a deletion extending from the closely linked supX locus into the trp operator-promoter region. The revertants were found to have regained initiation of expression of all five trp genes. Recombinational tests showed that in each case the genetic change responsible for re-initiation is cotransducible with the trp-cysB region of the chromosome. Two different mechanisms leading to re-initiation of trp gene expression were established: (a) an extension of the limits of the original deletion resulting in the fusion of the trp structural genes with a nearby gene or gene set located outside the operator end of trp, and (b) translocation of a duplicate set of the trp structural genes to other chromosomal sites, located operator-distal to the normal trp operon, in such a manner that they are functionally fused to foreign genetic units. One revertant which arose by mechanism (a) was shown to have an extended deletion with one new terminus in trp and the other in the nearby cysB locus. All the revertants exhibit constitutive expression of the trp enzymes, with activities varying among strains from five to forty five times greater than the fully repressed wild type level. The protein product of trpA, the first structural gene of the operon, appears to have been partially damaged by the re-initiation event in at least two strains, while in the other strains, the enzyme appears in preliminary tests to be indistinguishable from that of wild type.     

Transient expression in electroporated pea protoplasts: Elicitor responsiveness of a phenylalanine ammonia-lyase promoter

Summary High yields of viable pea protoplasts were produced from suspension cultured cells and the conditions for the optimum transient expression of the chloramphenicol acetyltransferase (CAT) gene fused to the CaMV 35S promoter after electroporation were investigated. Conditions for elicitor induction of a member of the phenylalanine ammonia-lyase (PAL) gene family in pea was also investigated using a chimeric gene carrying 480 bp of the putative promoter region of gPAL1 connected to bacterial cat gene and nos terminator. CAT activity was considerably induced by the treatment with fungal elicitor (>100 g/ml glucose equivalent) isolated from Mycosphaerella pinodes, a pea pathogen.Abbreviations CAT chloramphenicol acetyltransferase - PAL phenylalanine ammonia-lyase - CM acetylated chloramphenicol - GSH reduced glutathione - NOS nopaline synthase - ES electroporation solution - CaMV cauliflower mosaic virus - GUS -glucuronidase - CHS chalcone synthase - 2,4-D 2, 4-dichlorophenoxyacetic acid Present address: Research Institute, Takasago Perfumery Inc, 5-31-36, Kamata, Minato, Tokyo, 144, Japan Toso Inc, 4560 Oaza-Tomita, Shin-nanyo, Yamaguchi, 746, Japan Central Laboratory of Green Complex, Kasetsert University, Kamphaensaen, Nakohn Pathom, Thailand     

Structure and function of alpha-fetoprotein: a biophysical overview

alpha-Fetoprotein (AFP) is a large serum glycoprotein belonging to the intriguing class of onco-developmental proteins. AFP has attracted considerable attention since it was shown that the change in its serum level during pregnancy is a hallmark of the development of numerous embryonic disorders, while the increase in its content in the plasma of adults correlates with the appearance of several pathological conditions. Over the past 30 years, some 11000 papers have been published concerning AFP, an average rate of over a publication a day since 1969. The majority of publications are about the application of the protein in diagnostics, or about other uses of AFP in biomedicine; though some of them describe the biochemical and functional properties of AFP, two aspects have been extensively reviewed. However, surprisingly little is currently known about structural properties of this protein as well as about the molecular mechanism of its function. The present review pursues the aim to describe the current state of the art in studies of structural properties and conformational stability of AFP. An attempt to establish the relationship between conformational transformations in AFP and its function is also made.     

Functional analysis of the trans-acting factor binding sites of the mouse alpha-fetoprotein proximal promoter by site-directed mutagenesis.

The trans-acting factors of the mouse alpha-fetoprotein proximal promoter (-202 base pairs) are aligned as follows: regions Ia (HNF-1), Ib (C/EBP), II (NF-1 or C/EBP), II' (NF-1 or HNF-1), III (NP-III), IV (NP-IV), Va (NP-Va), and Vb (C/EBP). Site-specific mutation abolished protein binding to the corresponding mutated site with the exception of the NF-1 site, in which mutation causes partial protection. Transient expression analyses indicate that chloramphenicol acetyl-transferase (CAT) activity is reduced by mutations in regions Ia, II', Ib, II, and IV. Mutation of region III causes an increased activity and mutation of regions Va and Vb shows a slight inhibitory effect. Linking alpha-fetoprotein enhancer I to the wild type promoter resulted in a 12-fold stimulation of CAT activity. The activity of promoters with mutated C/EBP-binding sites (Ib, II, and Vb), was slightly above controls, indicating that enhancer I can reverse the effect of these mutations. Inhibition or stimulation of promoter activity resulting from mutations of the HNF-1 or NP-III binding sites, respectively, persisted when enhancer I was linked to the promoters, indicating that enhancer I cannot rescue these mutations. Mutation of both HNF-1-binding sites resulted in greater than 90% inhibition of CAT expression with and without enhancer I, indicating these sites are essential for promoter activity. The stimulation of promoter activity by mutation of the NP-III site suggests that this site may be essential for repression or attenuation of the alpha-fetoprotein gene. Our studies indicate that regulation of the alpha-fetoprotein gene requires the combinatorial effect of multiple cis- and trans-acting elements in the proximal promoter and that enhancer I may provide a factor(s) that specifically rescue the promoter from the inhibitory effect of mutation in the C/EBP-binding sites.     

Yolk sac: site of developmental microheterogeneity of mouse alpha-fetoprotein.

α-Fetoprotein was observed to be synthesized in mouse fetal liver and yolk sac by incorporation of radioactive leucine into appropriate tissue cultures. Cultured fetal liver during early (Day 13.5) and late (Day 16.5) development secreted predominantly the maximally sialylated Fp5. In contrast, the yolk sac secreted a developmentally changing array of α-fetoprotein: Day 11.5 yolk sac secreted predominantly the unsialylated Fp1, at Day 13.5, the yolk sac secreted all five electrophoretic forms of α-fetoprotein, and by Day 16.5, only Fp5 was predominantly secreted, as in the fetal liver. To ascertain whether the ³H-labeled proteins that appeared in the regions of α-fetoprotein on polyacrylamide gels represented α-fetoprotein, immunoprecipitations with anti-α-fetoprotein were carried out. After the immunoprecipitations, radioactivity in the regions of marker α-fetoprotein on polyacrylamide gels was decreased to background levels. When sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the immunoprecipitates was performed, radioactivity peaks comigrated with marker α-fetoprotein. The undersialylated α-fetoprotein forms do not appear to arise by loss of sialic acid following secretion as determined by mixing experiments of yolk sac and fetal liver in culture. The contribution of α-fetoprotein synthesized and secreted by fetal liver and yolk sac at Days 13.5 and 16.5 of development was compared. Day 13.5 yolk sac incorporated 6.7 times as much radioactivity into secreted α-fetoprotein as did fetal liver at this time. These results suggest that during early development, the yolk sac is primarily responsible for the synthesis and secretion of the undersialylated forms of α-fetoprotein. In addition to the microheterogeneity of α-fetoprotein attributed to the number of sialic acid residues attached to the glycoprotein, there appeared to be other changes in α-fetoprotein: Fp5 synthesized from fetal liver migrated slightly faster on polyacrylamide gels than that from yolk sac.     

Localization of DNA protein-binding sites in the proximal and distal promoter regions of the mouse alpha-fetoprotein gene.

DNase I footprinting assays were performed to identify the binding sites for putative trans-acting factors involved in the control of alpha-fetoprotein (AFP) gene expression using mouse AFP promoter fragments (-839 to +56) and nuclear protein extracts from fetal, newborn, and adult livers and from brain and kidney. Our studies have shown that with nuclear protein from adult mouse liver, there are 14 protected regions in the AFP promoter up to -839 base pairs (bp). Region I (-82 to -43) was protected by at least three different factors, one of which is CCAAT-binding/enhancer-binding protein. This region is highly conserved in the mouse, rat, and human AFP genes and has been shown previously to be essential for the regulation of tissue-specific expression in mouse. Differences in DNase I protection with fetal, newborn, and adult nuclear proteins have been observed in the proximal promoter region (up to -202 bp) and in regions further upstream (up to -839 bp). Significant differences among liver, kidney, and brain nuclear protein-binding sites have also been observed. In these studies, we have mapped the fetal and adult nuclear protein-binding sites of the cis-acting DNA sequences of the mouse AFP proximal promoter (up to -200) and have identified specific protein-binding sites in the distal promoter (-200 to -839). We have also identified the sites of the AFP promoter which bind nuclear proteins from highly differentiated tissues in which AFP is not expressed.